Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C

ConclusionsThe MTD of savolitinib was 400 mg qd in both cohorts. Data demonstrate an acceptable safety profile for savolitinib alone, or with osimertinib.Trial registration: Clinicaltrials.gov; NCT02143466; 21 May 2014.

Source: Targeted Oncology - May 3, 2021 Category: Cancer & Oncology Source Type: research